NCT05103046View on ClinicalTrials.gov

First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 23, 2021

Primary Completion Date

December 15, 2024

Study Completion Date

December 15, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

UCT-03-008

Orally available kinase inhibitor

Trial Locations (5)

30322

TERMINATED

Winship Institute of Emory University, Atlanta

75230

RECRUITING

Mary Crowley Cancer Research, Dallas

78229

TERMINATED

START (South Texas Accelerated Research Therapeutics), San Antonio

90095

RECRUITING

UCLA - JCCC Clinical Research Unit, Los Angeles

90505

TERMINATED

Torrance Memorial, Torrance

All Listed Sponsors
collaborator

Translational Research in Oncology

OTHER

lead

1200 Pharma, LLC

INDUSTRY